Skip to content
News
US Patent Granted for Nasodine in COVID-19

US Patent Granted for Nasodine in COVID-19


Firebrick Pharma’s patent application covering the use of Nasodine® Nasal Spray (Nasodine) in COVID-19 has been granted in the US.  The US patent dated 15 February 2022, is titled: “Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes.” A copy of the patent is available to view on the…

Nasodine in vitro and pilot human COVID-19 studies published

Nasodine in vitro and pilot human COVID-19 studies published


The results of in vitro studies of Nasodine® Nasal Spray (povidone-iodine 0.5%) against SARSCoV-2, and a pilot human study in a small number of COVID-19 subjects, have been published in the Australian Journal of Otolaryngology (AJO).  The paper titled: “In vivo (human) and in vitro inactivation of SARS-CoV-2 with 0.5% povidone-iodine nasal spray,” can be…

South African trial of Nasodine in COVID-19 receives local approval to proceed

South African trial of Nasodine in COVID-19 receives local approval to proceed


The Company’s planned clinical trial of Nasodine Nasal Spray (povidone-iodine 0.5%) in COVID-19 patients in South Africa, has received approval to proceed from the South African Health Products Regulatory Authority (SAHPRA).  The trial is titled: “Reduction of nasal shedding of SARS-CoV-2 in COVID-19 positive patients by the use of Nasodine® (povidone-iodine 0.5%) Nasal Spray.”  It…